The distinct role of secondary prevention in patients with prior coronary interventions

EuroIntervention

Volumn 5, Issue SUPPL. D, 2009, Pages

  Colmenarez, Humberto ^a   Escaned, Javier ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Coronary artery bypass surgery; Percutaneous coronary interventions; Secondary coronary revascularisation; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; COLESTIPOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PERINDOPRIL; PIOGLITAZONE; PLACEBO; PRAVASTATIN; QUINAPRIL; RAMIPRIL; RAPAMYCIN; RIMONABANT; ROSUVASTATIN; TELMISARTAN; THIENOPYRIDINE DERIVATIVE; TORCETRAPIB; UNINDEXED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG ELUTING STENT; DRUG MEGADOSE; GRAFT DYSFUNCTION; GRAFT OCCLUSION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVASCULAR ULTRASOUND; LOADING DRUG DOSE; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; SAPHENOUS VEIN GRAFT; SECONDARY PREVENTION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; PROGRAM DEVELOPMENT; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 77953660476     PISSN: 1774024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Scandinavian Simvastatin Survival Study Group (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Embrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610.
4. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: Pilot results. Arch Intern Med 2004;164:203-209.
5. Turley AJ, Roberts AP, Morley R, Thomley AR, Owens WA, de Belder MA. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: The need for targeted follow-up. Interact Cardiovasc Thorac Surg 2008;7:231-234.
6. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-1080.
7. Nissen SE, Nicholls SJ, Sipahi I, Libby P. Raichlen JS, Ballantyne CM. Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295:1556-1565.
8. Rodriguez-Granillo GA, Agonstoni P, Garcia-Garcia HM, Biondi-Zoccai GG, McFadden E, Amoroso G, de Jaegere P, Bruining N, de Feyter P, Serruys PW. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am J Cardiol 2007;99:5-10.
9. Nissen SE, Tuzcu EM. Libby P. Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004;292:2217-2225.
10. Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, de Winter S, Ligthart JM, Decker JW, Bertrand M, Simoons ML, Ferrari R, Fox KM, Remme W, De Feyter PJ, Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [perspective] study). Am J Cardiol 2007; 100:159-163.
11. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8. Fox KM.
12. Ryden L. Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J. Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I. Schernthaner G, Volpe M. Wood D. Guidelines on diabetes, pre-diabetees, and cardiovascular diseases: Executive summary. The task force on diabetes and cardiovascular diseases of the european society of cardiology (ESC) and of the european association for the study of diabetes (easd). Eur Heart J 2007; 28:88-136.
13. Cole JH, Jones EL, Craver JM, Guyton RA, Morris DC, Douglas JS, Ghazzal Z, Weintraub WS. Outcomes of repeat revascularization in diabetic patients with prior coronary surgery. J Am Coll Cardiol 2002;40:1968-1975.
14. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelliere R, Staniloae CS, Mavromatis K, Saw J. Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The periscope randomized controlled trial. JAMA 2008;299:1561-1573.
15. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression on coronary atherosclerosis. N Engl J Med 2007;356:1304-1316.
16. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM. Tuzcu EM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. The stradivarius randomized controlled trial. JAMA 2008;299:1547-1560.
17. Hassantash SA, Bikdeli B, Kalantarian S, Sadeghian M, Afshar H. Pathophysiology of aortocoronary saphenous vein bypass graft disease. Asian Cardiovasc Thorac Ann 2008; 16:331-336.
18. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-1317.
19. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardiol infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
20. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM, Jr., Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC, Jr., Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka JL, Hunt SA, Jacobs AK, Ornato JP. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: Summary article. A report of the american college of cardiology/american heart association task force on practice guidelines (committee to update the 1999 guidelines for coronary artery bypass graft surgery). J Am Coll Cardiol 2004;44:e213-310.
21. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-368.
22. Brophy JM, Brassard P, Bourgault C. The benefit of cholesterol-lowering medications after coronary revascularization: A population study. Am Heart J 2005;150:282-286.
23. Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL. Prognostic factors for atheroslerosis progression in saphenous vein grafts: The postcoronary artery bypass graft (post-CABG) trial. Post-cabg trial investigators. J Am Coll Cardiol 2000;36:1877-1883.
24. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol 2008;51:1938-1943.
25. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, Crijns HJ, van Gilst WH. Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). Quinapril on vascular ace and determinants of ischemia. Am J Cardiol 2001;87:542-546.
26. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
27. Sjoland H, Caidahl K. Lurje L, Hjalmarson A, Herlitz J. Metoprolol treatment for two years after coronary bypass grafting: Effects on exercise capacity and signs of myocardial ischaemia. Br Heart J 1995; 74:235-241.
28. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical effect. Circulation 2003;107:3003-3007.
29. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis. Circulation 2005;111:2906-2912.
30. Jaber WA, Lennon RJ, Mathew V, Holmes DR, Jr., Lerman A, Rihal CS. Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. J Am Coll Cardiol 2005;46:1473-1478.
31. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G. Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516.
32. Douglas JS, Jr., Holmes DR, Jr., Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-2832.
33. Rodriquez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF. Delgado J. Fernandez-Pereira C, Pocovi A, Rodriguez-Granilo AM, Schulz D, Raizner AE, Palacios I, O'Oneill W, Kaluza GL, Stone G. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: The prospective, randomized oral rapamycin in argentina (ORAR II) study. J Am Coll Cardiol 2006;47:1522-1529.
34. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhofer D, Schuhlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schomig A. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) trial. Circulation 2004;110:790-795.
35. Jorgensen B, Simonsen S, Endressen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the coronary angioplasty amlodipine restenosis study (CAPARES). J Am Coll Cardiol 2000;35:592-599.
36. Koo BK, Kim YS, Park KW, Yang HM, Kwon DA, Chung JW, Hahn JY, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Effect of celecoxib on restenosis after coronary angioplasty with a taxus stent (COREA-TAXUS trial): An open-label randomised controlled study. Lancet 2007;370:567-574.
37. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M. Pioglitazone reduces neointima volume after coronary stent implantation: A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005;112:2792-2798.
38. Holmes DR, Jr., Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB, 3rd, Lincoff AM, Tcheng JE, Chan R, Granett JR, Poland M. Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 2002;106:1243-1250.
39. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
40. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
41. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
42. Escaned J, Rydén L, Zamorano JL, Poole-Wilson P, Fuster V, Gitt A, Fernández-Avilés F, Scholte Op Reimer W, de Teresa E, Alonso-Pulpón L, Tendera M. Trends and contexts in European cardiology practice for the next 15 years: the Madrid Declaration: a report from the European Conference on the Future of Cardiology, Madrid, 2-3 June 2006. Euro Heart Journal 2007;28:634-7.
43. Archbold RA, Zaman AG, Curzen NP, Mills PG. Prescribing of ACE inhibitors and statins after bypass surgery: a missed opportunity for secondary prevention? Br J Cardio 2003;10:36-43.
44. Martin TN, Irving RJ, Sutherland M, Sutherland K, Bloomfield P. Improving secondary prevention in coronary bypass patients: closing the audit loop. Heart 2005;91:456-459.
45. Lifestyle and risk factor managememt and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572.
46. Carruthers KF, Dabbous OH, Flather MD, Starkey I, Jacob A, Macleod D, Fox KA. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart 2005;91:290-298.
47. Birkhead JS, Walker L, Pearson M, Weston C, Cunningham AD, Rickards AF. Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP). Heart 2004;90:1004-1009.
48. Fox DJ, Kibiro M, Eichhofer J, Curzen NP, Patients undergoing coronary revascularisation: A missed opportunity for secondary prevention? Postgrad Med J 2005;81:401-403.
49. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-3222.
50. Chan AW, Bhatt DL. Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG, Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696.